NeuroSense Therapeutics has released new data from their Phase 2b PARADIGM clinical trial which reveals a significant slowing of disease progression in high-risk ALS patients. These particular patients were treated with PrimeC, a drug formulated by the company, and showed a 43% slowing of disease progression, compared to results using a placebo. This was observed after six months of treatment.
This slowing of disease progression was also found in patients who had experienced symptoms of the disease for up to 12 months prior to the initial testing. These patients showed a 52% slowing in the disease's progression when compared to results using a placebo.
NeuroSense Therapeutics intends to utilize the data gathered in these specific patient group analyses to influence the design of their upcoming critical trial. The company believes this will increase the chances of the trial's success and boost cost-effectiveness.
Their lead drug candidate, PrimeC, is an extended-release oral combination of ciprofloxacin and celecoxib, two FDA-approved drugs. The PARADIGM clinical trial of PrimeC in ALS is a multinational, randomized, double-blind, placebo-controlled Phase 2b trial.
For more health news, visit rttnews.com.
